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Summary
In the liver, derangement of TGF-b signaling is associated with an increased incidence of hepatocellular carcinoma (HCC),
but the mechanism is not clear. We report here that forced expression of a major TGF-b signaling transducer, Smad3, re-
duces susceptibility to HCC in a chemically induced murine model. This protection is conferred by Smad3’s ability to pro-
mote apoptosis by repressing Bcl-2 transcription in vivo through a GC-rich element in the Bcl-2 promoter. We also show
that the proapoptotic activity of Smad3 requires both input from TGF-b signaling and activation of p38 MAPK, which occurs
selectively in the liver tumor cells. Thus, Smad3 enables the tumor suppression function of TGF-b by serving as a physiolog-
ical mediator of TGF-b-induced apoptosis.Introduction
Transforming growth factor b (TGF-b) regulates a diverse array
of cellular context-dependent biological processes ranging
from growth and differentiation to apoptosis (Massague´,
1998). In the liver, a major function of TGF-b, which is normally
produced by nonparenchymal stellate cells, is to limit regenera-
tive growth of hepatocytes in response to injury by inhibiting
DNA synthesis and inducing apoptosis (Oberhammer et al.,
1992; Romero-Gallo et al., 2005). As in other physiological set-
tings, the proapoptotic activity of TGF-b here is associated
with the removal of unwanted or damaged cells, thus playing
an indispensable role in maintaining normal cellular homeostasis
and organ size.
Hepatocellular carcinoma (HCC) is a common visceral malig-
nancy and among the leading causes of cancer death world-
wide (Parkin et al., 2005). It typically arises in a setting of
chronic hepatitis or cirrhosis, with infection by hepatitis B and
C viruses and chronic exposure to aflatoxin B together respon-
sible for about 80% of all HCC cases in humans (Thorgeirsson
and Grisham, 2002; Block et al., 2003). Although the patho-
genic causes are well known, no effective treatment is available
for most HCC patients except for surgical resection and liver
transplantation in the few cases detected at a sufficiently early
stage (Varela et al., 2003). TGF-b has a complex role in HCC; it
is persistently induced during hepatitis and promotesCANCER CELL 9, 445–457, JUNE 2006 ª2006 ELSEVIER INC. DOI 10.10progression of cirrhosis by accelerating extracellular matrix de-
position (Takiya et al., 1995; Wrana, 1999). Persistent upregula-
tion of TGF-b is also a hallmark of HCC in humans, leading to
the speculation that TGF-b may accelerate neoplastic growth
of liver cancer (Rossmanith and Schulte-Hermann, 2001). How-
ever, mice heterozygous for a target-inactivated TGF-b1 allele
or a TGF-b type II receptor allele show heightened susceptibility
to chemical carcinogens such as N-diethylnitrocosamine com-
pared to their wild-type littermates, indicating a haploinsuffi-
ciency of tumor suppression (Tang et al., 1998; Im et al.,
2001; Kanzler et al., 2001). In rodent HCC models established
by transgenic expression of c-myc/TGF-a or induced chemi-
cally, attenuation of TGF-b signaling was observed as result
of downregulation of TGF-b type II receptor (Reisenbichler
et al., 1994; Santoni-Rugiu et al., 1999). Apparently, the antipro-
liferative and proapoptotic roles of TGF-b represent a ‘‘fail-
safe’’ oversight that has to be evaded by tumor cells to gain
malignancy, but the mechanism of this tumor suppression is
not fully understood.
Signaling of TGF-b is mediated by a complex of membrane
bound type I and type II receptors and Smad proteins that in-
teract with and are phosphorylated at the C-terminal SSXS
motif by the serine-threonine kinase domain of the type I
receptor (Derynck and Zhang, 2003; Shi and Massague´,
2003). Of the eight Smads identified, Smad2 and Smad3
mediate TGF-b/activin signaling. Once activated, theseS I G N I F I C A N C E
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A R T I C L EFigure 1. Expression of Smad3 transgenes in hepatocytes
A: Schematic illustration of Smad3, Smad3SD, and Smad3Dc transgenes.
B: Dox-controllable expression of Smad3 transgenes in livers of LAP/S3, LAP/S3SD, and LAP/S3Dc doubly transgenic mice as analyzed by RT-PCR amplification
of total liver RNA with primers denoted by arrows in A. Transgenic animals were sacrificed 2 weeks after dietary Dox withdrawal.
C: Western analysis of Smad3 transgenes in liver extracts. Fold increase of transgenic relative to endogenous Smad3 level (LAP-tTA control mice) is indicated.
D: Immunohistochemistry staining of Smad3 (brown) in liver sections. Both endogenous and transgenic wild-type Smad3 as well as Smad3Dc showed exclusive
cytoplasmic staining in resting hepatocytes, whereas Smad3SD exhibited strong nuclear staining. Scale bar, 60 mm.receptor-specific Smads associate with Smad4 and traverse
into the nucleus to regulate expression of target genes. It is
now increasingly appreciated that MAPKs such as Erk, JNK,
and p38, as well as cyclin-dependent kinase CDK2/4, also
phosphorylate Smads at various sites in the linker region bridg-
ing the two conserved MH1 and MH2 domains (Kretzschmar
et al., 1999; Engel et al., 1999; Matsura et al., 2004; Mori
et al., 2004). These latter phosphorylation events may either in-
hibit or enhance Smad activity. While it is established that
TGF-b exerts growth inhibition via its ability to downregulate
the proto-oncogene c-myc and to activate transcription of cy-
clin-dependent kinase inhibitors, such as p15ink4b and p21cip1,
much less is known regarding the mechanism of TGF-b-in-
duced apoptosis (Derynck et al., 2001). Recent studies in cell
culture systems have revealed a number of factors including
ARTS, DAXX, and DAP kinase that appear to act through the
apoptotic apparatus (Larisch et al., 2000; Perlman et al.,
2001; Jang et al., 2002), and that Smad3 is sequestered in a cy-
toplasmic complex with survival kinase PKB/Akt, which re-
strains Smad3 from entering the nucleus and activating the ap-
optotic program independent of the kinase activity (Conery
et al., 2004; Remy et al., 2004).
To investigate the role of Smad3 in tumorigenesis, we gener-
ated several lines of transgenic mice expressing Smad3 and its
mutated variants under the control of the tetracycline repress-
ible system and specifically induced the expression of Smad3
transgenes in the liver. We report here that livers with elevated
Smad3 are protected from chemically induced carcinogenesis
and demonstrate that Smad3 potentiates apoptosis by repres-
sing Bcl-2 transcription in vivo through a GC-rich element in
the Bcl-2 P2 promoter.446Results
Regulated expression of Smad3 transgenes in
hepatocytes
At the outset of this study, we used a plasmid vector that confers
controllable cDNA expression via the tetracycline-responsive el-
ement (TRE) to create several lines of transgenic mice express-
ing wild-type Smad3, constitutively active Smad3SD with the
last two serines substituted by aspartic residues to mimic phos-
phorylation, or dominant-negative Smad3Dc lacking the last
four amino acid residues, SSVS (Figure 1A). Liver-specific
expression of transgenes was achieved by crossing TRE-
Smad3, TRE-Smad3SD, or TRE-Smad3Dc mice with LAP-tTA
mice, which express tetracycline transactivator (tTA) specifically
in hepatocytes under the control of the liver activator protein
(LAP) promoter (Kistner et al., 1996). To avoid potential develop-
mental complications, the expression of Smad3 transgenes was
held off by feeding each mating pair and their newborn offspring
with doxycycline (Dox), an inhibitor of tTA transactivator, until
the doubly transgenic offspring were 3 weeks of age or as noted.
Two high-expressing strains derived from the intercrosses be-
tween separate TRE-Smad founders of each transgenic line
and the LAP-tTA mice were selected for further analyses (Fig-
ures 1B and 1C). These doubly transgenic mice were designated
hereafter as LAP/S3, LAP/S3SD, or LAP/S3Dc, respectively.
Western blot analysis confirmed the elevated expression of
transgene products in respective liver extracts (Figure 1C),
and immunohistochemistry staining indicated that both endog-
enous and transgenic Smad3 and Smad3Dc were localized ex-
clusively in the cytoplasm of otherwise normal hepatocytes, but
Smad3SD was enriched in the nucleus (Figure 1D). Despite theCANCER CELL JUNE 2006
A R T I C L EFigure 2. Ectopic expression of Smad3 protects
liver from chemically induced carcinogenesis
A: Percentage of mice developed at least one
liver tumor at the end of 6th (n = 9) or 9th (n =
10) month after DEN injection. A separate graph
shows the percentage of mice with at least one
malignant carcinoma at 9th (n = 10) month after
DEN injection.
B: Average number of lung tumors per animal at
9th month after DEN injection (n = 10).
C–F: H&E staining of liver sections. No macro-
scopic tumor was detected in livers from LAP/
S3 and LAP/S3SD mice. Scale bar, 5 mm.
G–J: Higher magnification of liver sections in C–F
showing eosinophilic hepatocellular adenomas
found in LAP-tTA, LAP/S3, and LAP/S3SD mice
and a hepatocellular carcinoma in a LAP/S3Dc
mouse. Note the size of adenomas from LAP/S3
and LAP/S3SD livers is much smaller than that
from LAP-tTA or LAP/S3Dc livers. Arrowheads de-
note the tumor margin. Scale bar, 50 mm.
Kand L:Density of average number of tumors per
cm2 liver area (K) and percentage of tumor in to-
tal liver area (L) measured in liver sections.
M: Density of average number of tumors per cm2
liver area. Dox was either taken out of the diet
when mice were 3 weeks of age (Dox off, 3W),
taken out of the diet 6 months after DEN/Pb
treatment (Dox off, 6M), or kept in the diet at
all times (Dox on).
All analyses in this figure were carried out 9
months after DEN injection except where other-
wise indicated. In B, K, L, and M, each cohort
consisted of ten mice. *p < 13 1025. Error bars in-
dicate mean 6 standard deviation.overexpression of these Smad3 transgenes, however, none of
the doubly transgenic offspring manifested any discernible phe-
notype in resting livers (Figures S1 and S2 in the Supplemental
Data available with this article online; and data not shown).
Ectopic expression of Smad3 protects liver from
chemically induced carcinogenesis
To investigate the role of Smad3 in liver tumorigenesis, we sub-
jected the above three lines of doubly transgenic mice as well as
the control LAP-tTA mice to a well-established chemical carci-
nogenesis protocol because the murine tumors developed un-
der this protocol most faithfully recapitulate the human cancer
both in tumor morphology and in pathological progressionCANCER CELL JUNE 2006(Pitot, 1990; Tamano et al., 1994; Masui et al., 1997). Thus, liver
tumor formation was initiated by a single injection of diethylni-
trosamine (DEN) at 5 weeks of age after Smad3 transgenes
were turned on, and promoted by continuous administration of
phenobarbital (Pb) starting at 9 weeks of age. Nine months
into this protocol, all control LAP-tTA and LAP/S3Dc mice devel-
oped multiple macroscopic tumor nodules in the liver (Figures
2A, 2C, and 2F), with an average of three to four tumors per
square centimeter (Figure 2K) and the neoplasm accounting
for about 40% of total liver area (Figure 2L). Although similar in
eventual numbers and sizes to the controls, liver tumors of
LAP/S3Dc mice had an earlier onset, beginning at the sixth
month after DEN injection (Figure 2A), suggesting that447
A R T I C L EFigure 3. Smad3 promotes apoptosis of liver tumor cells in vivo
A: Immunostaining of active TGF-b1 (green) in normal and neoplastic tissues of LAP-tTA control liver. Cell nuclei were counterstained with DAPI (blue). Scale
bar, 10 mm.
B: Thymidine incorporation assay of primary hepatocytes in the presence (Dox on) or absence of Dox (Dox off).
C: Immunohistochemistry staining of the proliferation marker Ki67 (brown) in normal and neoplastic tissues of LAP-tTA liver. Scale bar, 100 mm.
D: Quantification of Ki67-positive cells in normal and neoplastic liver tissues.
E: TUNEL assay of apoptotic cells (green) in tumors. Cell nuclei were counterstained with DAPI (blue). Scale bar, 100 mm.
F: Quantification of TUNEL-positive cells in normal and neoplastic liver tissues.
In D and F, the results represent mean values of 12 tumors, except in the case of LAP/S3SD, in which the mean value was derived from four tumors. Error bars
indicate mean 6 standard deviation.dominant-negative inhibition of Smad3 function accelerates he-
patic tumor progression. Pathohistological analysis indicated
that, while most tumor nodules present in these mice were eo-
sinophilic hepatocellular adenomas (Figure 2G and data not
shown), poorly differentiated trabeculae typical of advanced
carcinomas could be occasionally found in the center of large
adenomas (Figures 2A and 2J). In contrast, no macroscopic tu-
mor was found in the livers of LAP/S3 or LAP/S3SD mice (Fig-
ures 2D and 2E). When scrutinized under a microscope at high
magnification, only 60% of LAP/S3 and 30% of LAP/S3SD
mice developed liver tumors at the ninth month, respectively
(Figure 2A), but the number of tumor nodules was few
(Figure 2H-I, 2K) and the size was small (Figures 2H, 2I, and
2L). This reduced tumor formation can be attributed specifically
to ectopic expression of Smad3 in the liver because primary
lung tumors, frequently observed in this carcinogenesis proto-
col, appeared at a similar rate in all three transgenic and the con-
trol lines after DEN/Pb exposure (Figure 2B). Moreover, when
continuously kept on the Dox diet, the extent of liver tumor for-
mation in LAP/S3 mice was comparable to that of LAP/S3Dc
mice (Figure 2M). Thus, enhancing Smad3 function through ec-
topic expression of wild-type Smad3 or Smad3SD protects the
liver from chemically induced carcinogenesis, whereas disrup-
tion of this function by dominant-negative Smad3Dc has the448opposite effect. This protection is likely conferred by suppres-
sion of tumor progression rather than prevention of tumor initia-
tion because tumor formation was equally reduced when
Smad3 transgenes were induced by dietary Dox withdrawal ei-
ther before or 6 months after the tumor-initiating DEN injection
(Figure 2M).
Smad3 suppresses liver tumorigenesis by promoting
apoptosis in tumor cells
In mammals, production and paracrine release of active TGF-b
increase substantially accompanying liver regeneration after in-
jury, or during hepatocarcinogenesis (Wrana, 1999; Rossmanith
and Schulte-Hermann, 2001). We observed such an increase of
the level of active TGF-b1, the predominant variant of three TGF-
b isoforms, in the hitherto described DEN/Pb-induced tumors
(Figure 3A). Thus, it is possible that the ectopically expressed
Smad3 renders hepatocytes hyperresponsive to this endoge-
nous release of TGF-b, effectively amplifying its tumor-suppres-
sive role either through growth inhibition or apoptosis. Con-
versely, dominant-negative Smad3Dc could accelerate liver
carcinogenesis by blocking endogenous TGF-b signaling, and
thus the TGF-b-mediated tumor suppression. Indeed, in isolated
primary hepatocytes, TGF-b treatment led to a 50% reduction in
proliferation of the liver cells expressing normal levels of Smad3CANCER CELL JUNE 2006
A R T I C L E(Figure 3B, LAP-tTA cells or Dox on). Further reduction of prolif-
eration was seen in cells expressing elevated Smad3 or
Smad3SD, but this reduction was abolished in cells expressing
Smad3Dc (Figure 3B, Dox off), suggesting that the growth of cul-
tured hepatocytes is subject to control by the TGF-b pathway.
However, this control appeared to be lost in the DEN/Pb-induced
liver tumors because the tumor cell growth, measured by immu-
nohistochemistry staining of the Ki67 proliferation marker in tu-
mor sections (Figure 3C), did not change among various
Smad3 transgenic strains (Figure 3D). Outside the tumor tissue,
proliferation was extremely low and also did not change in re-
sponse to transgene expression (Figures 3C and 3D). Instead,
the number of apoptotic cells increased substantially in the tu-
mors of LAP/S3 and LAP/S3SD mice as evidenced by TUNEL as-
say (Figures 3E and 3F). These results suggest that, while liver tu-
mors developed in all transgenic lines may have gained an ability
to escape TGF-b-mediated growth inhibition, they succumb to
a high rate of apoptosis when the function of Smad3 is enhanced.
Smad3 enhances the responsiveness of hepatocytes
to apoptosis
In light of the propensity of LAP/S3 and LAP/S3SD liver tumors to
undergo apoptosis, we postulate that the reduced susceptibility
of LAP/S3 and LAP/S3SD mice to HCC is due to a heightened
sensitivity of ‘‘precancerous’’ liver cells to apoptotic stimuli as re-
sult of enhanced Smad3 function. To test this hypothesis, we ex-
amined the hepatic response of the above transgenic lines to ac-
tivation of the death receptor Fas, a potent inducer of liver
apoptosis. Fas antigen is ubiquitously expressed in hepatocytes
and downregulation of Fas-mediated apoptosis is one of the
prominent characteristics of liver tumors (Galle et al., 1995; Ito
et al., 1998; Pinkoski et al., 2000). In vivo, mice are known to
be sensitive to Fas and become moribund after injection of Jo-
2 antibody, a Fas agonist, due to massive liver failure (Ogasa-
wara et al., 1993; Leu et al., 2003). We first detected signs of liver
injury and apoptosis in LAP/S3 and LAP/S3SD mice 3 hr after in-
jection of Jo-2 antibody (Figures 4A and 4B); by 5 hr, these signs
intensified and death ensued (Figure 4C). In each case, however,
the magnitude of cell death and hemorrhagic liver destruction in
LAP/S3 and LAP/S3SD mice was much greater than that of the
controls (Figures 4B and 4D), and the mortality of LAP/S3 and
LAP/S3SD mice also superseded that of the control mice by
1.5 hr (Figure 4C). In contrast, both liver injury and cell death
were subdued in LAP/S3Dc mice (Figures 4A and 4B) to such
an extent that more than half of the animals in this cohort sur-
vived Jo-2 injection (Figure 4C). In line with these physiological
changes, the caspase cascade was activated strongly in LAP/
S3 and LAP/S3SD, weakly in LAP-tTA, but minimally in LAP/
S3Dc livers 3 hr after Jo-2 injection (Figure 4E). Concurrent
with the above Fas-induced physiological and molecular
changes, Smad3 was C-terminally phosphorylated in the liver
(Figure 4F) and translocated into the nucleus (Figure 4G), but
both of these two events were blocked by Smad3Dc (Figures
4F and 4G). Thus, although ectopic expression of Smad3 per
se causes no phenotypic manifestation in the liver, it nonetheless
increases the tendency of hepatocytes to undergo apoptosis.
Proapoptotic activity of Smad3 requires its nuclear
translocation and activation of p38 MAPK
As in liver tumors, we detected a release of active TGF-b1
shortly after Jo-2 injection (Figure 5A), most likely stemmingCANCER CELL JUNE 2006from nonparenchymal stellate cells. This suggests that the proa-
poptotic role of Smad3 in hepatocytes may require activation of
the hepatic TGF-b pathway. To test this hypothesis, we isolated
primary hepatocytes from the transgenic Smad3, Smad3SD,
Smad3Dc, and control mice. When grown in normal medium
rich in serum, hepatocytes are refractory to TGF-b but succumb
to TGF-b-induced apoptosis when deprived of serum and insu-
lin (Tanaka and Wands, 1996; Chen et al., 1998). In the serum-
starved setting, we found that TGF-b-induced apoptosis was
augmented in LAP/S3 and LAP/S3SD but suppressed in LAP/
S3Dc hepatocytes compared to the controls (Figure 5B). Modu-
lation of the TGF-b-induced apoptosis was specific to Smad3
transgenes, as it was absent in cells that were cultured in
Dox-containing medium (Figure 5B). The requirement of
Smad3 for triggering cell death in hepatocytes was further cor-
roborated by Smad3-siRNA-mediated RNA interference of the
apoptotic response (Figure 5C). It is believed that survival kinase
PKB/Akt normally sequesters Smad3 in a cytoplasmic protein
complex and, when it is inactivated by serum deprivation, re-
leases Smad3 to translocate into the nucleus (Conery et al.,
2004; Remy et al., 2004). However, the fact that ectopic expres-
sion of Smad3SD in the liver of LAP/S3SD mice did not cause
any phenotype even when Smad3SD was localized to the nu-
cleus argues that C-terminal phosphorylation and nuclear trans-
location alone are probably not sufficient to render Smad3 fully
active in inducing apoptosis. Since both Fas activation and se-
rum deprivation are known to activate JNK and p38 MAPK (Goil-
lot et al., 1997; Juo et al., 1997; Kummer et al., 1997), two impor-
tant regulators of apoptosis in hepatocytes, we speculated that
the activation of such kinases might be an additional require-
ment for staging full proapoptotic activity of Smad3. Indeed, im-
munohistochemistry staining showed that p38 MAPK was acti-
vated in DEN/Pb-induced liver tumors but not in normal liver
tissues, regardless of the expression of Smad3 transgenes
(Figure 5D). No such difference in the activation status of JNK
was observed (data not shown). To directly test the role of p38
MAPK, we treated normal hepatocytes with various kinase in-
hibitors and found that only SB203580, a specific p38 MAPK in-
hibitor, blocked the TGF-b-induced apoptosis (Figure 5E).
Treating hepatocytes with JNK, Erk, and Akt kinase inhibitors
actually enhanced the apoptotic response, whereas ROCK ki-
nase inhibitor had no effect (Figure 5E). These results demon-
strate that the proapoptotic activity of Smad3 in hepatocytes
requires nuclear translocation governed by C-terminal phos-
phorylation as well as activation of p38 MAPK.
Downregulation of Bcl-2 by TGF-b/Smad3
In search of a Smad3 target for its role in hepatocytic apoptosis,
we assayed a number of important apoptotic regulators includ-
ing Bcl-2, Bcl-xL, Bax, Bad, and Bak in Fas-activated liver ex-
tracts. Western analyses indicated that the level of Bcl-2 was
downregulated in liver extracts prepared after the animals
were injected with Jo-2 (Figure 6A), consistent with the role of
Bcl-2 as a key antiapoptotic inhibitor (Gross et al., 1999). The
suppression of Bcl-2 was more prominent in LAP/S3 and LAP/
S3SD extracts but abrogated in LAP/S3Dc extracts (Figure 6A).
No detectable fluctuation of other members of the Bcl-2 family
was observed (Figure 6A and data not shown). RT-PCR analy-
ses of total liver RNA showed that the level of Bcl-2 mRNA
was likewise decreased in response to Fas activation, and this
decrease was augmented by the presence of ectopic Smad3449
A R T I C L EFigure 4. Smad3 enhances the responsiveness of hepatocytes to Fas-mediated apoptosis
A: Liver function of transgenic mice (n = 4) measured as serum alanine aminotransferase (ALT) activity (n = 4).
B:Quantification of TUNEL-positive cells in liver sections of transgenic mice (n = 4) after Fas activation. Mean values compiled after counting five magnification
(203) fields for each liver are shown.
C: Kaplan-Meyer survival curve of each transgenic strain after Fas activation (n = 10).
D: H&E staining of liver sections after Fas activation. Scale bar, 250 mm.
E: Western analysis of caspase cleavage in liver extracts. Arrowheads denote cleaved products of caspases.
F: Western analysis of phospho-Smad3 and total Smad3 in liver extracts.
G: Immunohistochemistry staining of Smad3 (brown) in liver sections 3 hr after Jo-2 injection. Scale bar, 50 mm. Note that wild-type Smad3 (endogenous or
transgenic) in LAP-tTA and LAP/S3 accumulated in the nucleus after Fas was activated, while total Smad3 in LAP/S3Dc mice was still retained in the cytoplasm
of hepatocytes.
Error bars indicate mean 6 standard deviation.or Smad3SD and diminished by Smad3Dc (Figure 6B), suggest-
ing that Bcl-2 is regulated transcriptionally by Smad3. Similarly,
immunohistochemistry staining of Bcl-2 appeared to be de-
creased in liver tumor sections derived from LAP/S3 and LAP/
S3SD mice compared to a persistent high level in tumor sections
from LAP-tTA and LAP/S3Dc mice (Figure 6C). This finding is
consistent with the apoptotic indexes exhibited by the tumor
samples. To investigate whether the same TGF-b/Smad3-medi-
ated repression of Bcl-2 also operates in human liver tumor
cells, we expressed N-terminal FLAG-tagged Smad3 and
Smad3Dc in human hepatoma SK-Hep-1 cells by retrovirus-me-
diated transduction and examined the Bcl-2 protein levels in
these cells. TGF-b treatment decreased the level of Bcl-2450protein in the SK-Hep-1 cells infected with an empty vector;
this reduction was enhanced by forced expression of Smad3
while reversed by Smad3Dc (Figure 6D). To test whether the
TGF-b-induced apoptosis can be accounted for by reduction
of the Bcl-2 level, we infected SK-Hep-1 cells and Hep3B cells,
another line of human hepatoma, with recombinant adenovi-
ruses carrying either a copy of the Bcl-2 cDNA or the control
b-galactosidase cDNA. Forced expression of Bcl-2 in both lines
of hepatoma cells inhibited the apoptotic response induced by
TGF-b (Figure 6E). Taken together, the above results indicate
that TGF-b/Smad3 signaling has a direct role in controlling the
cellular level of Bcl-2, which is critical for the TGF-b-mediated
apoptosis in the liver.CANCER CELL JUNE 2006
A R T I C L EFigure 5. Dual requirements of Smad3 and p38 MAPK in TGF-b-induced apoptosis
A: Immunostaining of active TGF-b1 in mock or Fas-activated liver sections as in Figure 3A. Scale bar, 10 mm.
B: ELISA assay of DNA fragmentation (Cell Death Detection Kit, Roche) as a function of apoptosis in primary hepatocytes isolated from transgenic mice in the
presence or absence of Dox, and/or TGF-b.
C: Specific requirement of Smad3 in TGF-b-induced apoptosis in primary hepatocytes. The specificity of Smad siRNAs is shown in the Western analysis of siRNA-
transfected hepatocytes in the left panel. NS, nonsilencing control siRNA.
D: Immunohistochemistry staining of phospho-p38 in liver sections. Note that the weak brown staining of phospho-p38 MAPK is concentrated in the interstitial
stellate cells in nontumor tissue, whereas it is highly induced in hepatocytes in the tumors. Scale bar, 50 mm.
E: Requirement of p38 MAPK but not JNK, Erk, Akt, or ROCK in TGF-b-induced apoptosis in primary hepatocytes. Cell death was monitored by ELISA assay as
in B.
Error bars indicate mean 6 standard deviation.Transcriptional repression of Bcl-2 by Smad3
Previously, a decrease of Bcl-2 levels has been observed in
TGF-b-mediated apoptosis in several other types of cells
(Sa´nchez-Capelo, 2005). However, the underlying molecular
mechanism has not been addressed, nor is it clear whether this
reduction is due to direct transcriptional repression by TGF-
b signaling. In mammals, transcription of theBcl-2 gene is driven
by a TATA-less, upstream promoter (P1), and a downstream
promoter (P2) (Heckman et al., 2000). When assayed in the
Hep3B line of human hepatoma cells, we found that the down-
stream P2 promoter was repressed by TGF-b (Figure 7A); this
repression was enhanced by cotransfected Smad3 but com-
pletely blocked by Smad3DC (Figure 7B). Similar results were
obtained in SK-Hep-1 cells (Figure 7B). This observation was
further substantiated in a similar experiment using Smad-
specific siRNAs, in which the TGF-b-induced repression of the
P2 promoter was specifically blocked by interfering with the
function of endogenous Smad3 but not Smad2 (Figure 7C). Con-
sistent with the promoter reporter assays, Smad3- but not
Smad2-specific siRNA also diminished the TGF-b-mediated
downregulation of endogenous Bcl-2 protein levels (Figure
7D). Thus, Smad3 is essential for the transcriptional repression
of Bcl-2 and apoptosis induced by TGF-b.CANCER CELL JUNE 2006To delineate the molecular mechanism of Smad3-mediated
transcriptional repression of Bcl-2, we conducted promoter
mapping studies in transfected Hep3B cells and identified a re-
gion between 2802 bp and 2747 bp upstream from the trans-
lational initiation site of the Bcl-2 gene (Figure 8A). This region
encompasses three overlapping copies of a GC-rich repeat,
which is conserved between the human and mouse genes and
is identical to the Drosophila Mad binding element, GCCGnCGc
(Kim et al., 1997). Mutation studies showed that altering three
nucleotides in the GC-rich region was sufficient to abolish the
TGF-b/Smad3-mediated repression (Figure 8B), and the signif-
icance of these Smad binding elements was further demon-
strated in an experiment employing Smad3 siRNA, which com-
pletely ablated the TGF-b-mediated repression of the wild-type
Bcl-2 reporter (2802) while having no effect on the mutant re-
porter (2802m) (Figure 8C). Incubating a Smad3 DNA binding
domain fusion protein, GST-Smad3NL, with a radioactively la-
beled double-stranded DNA probe containing the GC-rich re-
gion, resulted in an electrophoretic mobility shift that could be
competed away with unlabeled competitor DNA but not its mu-
tant variants (Figure 8D). Addition of Smad3 antibody caused
a supershift of the DNA-protein complex, suggesting a specific
binding between Smad3 and the DNA element. To determine451
A R T I C L EFigure 6. Smad3 downregulates Bcl-2 expression
A:Western analysis of different Bcl-2 family mem-
bers and Akt in liver extracts from mice treated
with or without Jo-2.
B: RT-PCR analysis of Bcl-2 and Bcl-xL mRNA in
liver extracts of A. RNA from two different livers
was used for each group.
C: Immunohistochemistry staining of Bcl-2 in liver
tumors after 9 months of DEN/Pb treatment. Rep-
resentative data of four tumor samples in each
cohort are shown. Scale bar, 100 mm.
D: Western analysis of endogenous Bcl-2 protein
levels in retrovirus-infected SK-Hep-1 cells ex-
pressing LPCX vector, FLAG-tagged Smad3, or
Smad3Dc. Cell lysates were collected after
TGF-b treatment for 24 hr. Expression of FLAG-
tagged Smad3 or Smad3Dc is shown in the mid-
dle panel. Endogenous GAPDH was used as the
loading control (bottom panel). *Nonspecific
band.
E: Suppression of TGF-b-induced apoptosis in
Hep3B and SK-Hep-1 cells by adenovirus-medi-
ated expression of Bcl-2. Expression of Bcl-2 in
the Hep3B and SK-Hep-1 cell lysates was con-
firmed by a Western analysis in right panel.
Note that TGF-b treatment did not affect the
level of exogenous Bcl-2 protein.
Error bars indicate mean 6 standard deviation.whether this interaction occurs in vivo, we performed a chroma-
tin immunoprecipitation (ChIP) assay first in liver tissues isolated
from transgenic animals that had been injected with Jo-2 anti-
body or saline control. After precipitation with Smad3 antibody
and amplification by PCR, a DNA fragment containing the GC-
rich region was detected in Fas-activated liver extracts obtained
from LAP-tTA, LAP/S3, and LAP/S3SD but not LAP-S3DC mice
(Figure 8E). In a reciprocal experiment, we performed the ChIP
assay with an antibody specific for acetylated histone H4, which
is generally associated with transcription-active promoter ele-
ments (Grunstein, 1997). In this case, the DNA fragment contain-
ing the GC-rich region was amplified from all samples except the
Fas-activated LAP-tTA, LAP/S3, or LAP/S3SD extracts (Fig-
ure 8E). We next repeated this entire set of experiments directly
in isolated primary hepatocytes cultured in the absence of Dox.
After immunoprecipitation with an anti-Smad3 antibody, the
DNA fragment containing the GC-rich region of Bcl-2 promoter
was amplified from lysates of hepatocytes isolated from LAP-
tTA, LAP/S3, and LAP/S3SD, but not LAP/S3Dc mice and only
when the cells were pretreated with TGF-b (Figure 8F). Clearly,
the interaction between Smad3 and the Bcl-2 P2 promoter cor-
related with a repressed state of transcription in vivo as demon-
strated by ChIP assay using the acetylated histone H4-specific
antibody. Taken together, these results demonstrate that Bcl-2
is a bona fide physiological target of TGF-b/Smad3 signaling452and suggest that activation of TGF-b/Smad3 signaling amplifies
the effect of proapoptotic cues such as death receptor activa-
tion or carcinogenesis through transcriptional repression of
Bcl-2.
Discussion
TGF-b-induced apoptosis plays an important role in many bio-
logical processes such as involution of mammary epithelium,
wound healing, elimination of immature lymphocytes, and liver
regenerative growth, but the molecular path that leads to its cel-
lular context-dependent activation is not well defined. Unlike
death receptor ligands, engagement of the TGF-b signaling
pathway does not cause obligatory apoptosis. For this reason,
TGF-b-induced apoptosis of cultured cells invariably requires
simultaneous removal of serum survival factors. Recent data
suggest that the proapoptotic activity of Smad3 is regulated
by PKB/Akt in response to cell survival factors via a kinase-inde-
pendent interaction, which restrains Smad3 from entering the
nucleus and activating apoptosis (Conery et al., 2004; Remy
et al., 2004). This model is useful in explaining the sensitivity of
cultured cells to TGF-b-induced apoptosis but does not specify
a mechanism for the TGF-b/Smad3 action. In the current study,
we created conditions in which the Smad3 activity in hepato-
cytes was manipulated by ectopic expression of wild-typeCANCER CELL JUNE 2006
A R T I C L ESmad3, or its dominant-negative or constitutively active mutant.
We show here that the responsiveness of hepatocytes to apo-
ptotic stimuli changes according to the expression of Smad3
transgenes, and we present evidence that identifies Bcl-2 as
a direct transcriptional target of the proapoptotic activity of
Smad3. These findings are consistent with the previous notion
that TGF-b-induced apoptosis is accompanied by reduced mi-
tochondrial transmembrane potential and release of cyto-
chrome c (Freathy et al., 2000). Thus, by attenuating the level
of a major apoptosis inhibitor, Bcl-2, TGF-b/Smad3 signaling
facilitates a permissive cellular context that is conducive to
apoptosis.
In previous cell culture and biochemical studies, Smad3SD
with two phosphorylation-mimicking aspartic acid substitutions
behaves as a constitutively active mutant and is able to form
a homo- or heterotrimeric Smad complex, suggesting that C-
terminal phosphorylation is sufficient to activate the transcrip-
tional activity of Smad3 (Feng et al., 1998; Chacko et al.,
2001). Our current data indicate, however, that while Smad3SD
is nuclear, it does not induce apoptosis by itself in normal hepa-
tocytes. It is possible that either C-terminal phosphorylation
alone is not sufficient to fully activate the proapoptotic activity
of Smad3, or an independent apoptotic input is required, given
the auxiliary nature of TGF-b signaling in apoptosis. Indeed, our
data show that p38 MAPK is preferentially activated in liver tu-
mor cells that have the propensity to sustain a high rate of apo-
ptosis as result of ectopic expression of Smad3, and activation
Figure 7. Smad3 represses Bcl-2 transcription
A: Luciferase assays of different Bcl-2 promoter reporters in transfected
Hep3B cells. One day after transfection, the cells were treated with TGF-
b for 20 hr.
B: Luciferase assays of the Bcl-2 P2 (21278) promoter reporter in transfected
Hep3B or SK-Hep-1 cells as in A.
C: Luciferase assays of the Bcl-2 P2 (21278) promoter reporter in the pres-
ence of nonsilence control (NS), Smad2, or Smad3 siRNA. The siRNAs were
cotransfected with reporter DNAs, and 2 days after transfection, the cells
were treated with TGF-b for 20 hr.
D: Western analysis of Bcl-2 expression in SK-Hep-1 cell lysates after 2 days of
the siRNA transfection.
Error bars indicate mean 6 standard deviation.CANCER CELL JUNE 2006of p38 MAPK is required for TGF-b-induced apoptosis in normal
hepatocytes. At present, it is not clear whether p38 MAPK is ac-
tivated in liver tumors by a Smad-independent, noncanonical
TGF-b signaling mechanism as we reported previously in mouse
mammary epithelial cells (Yu et al., 2002), or it is activated by mi-
togenic cues emanated from tumor milieu. Nevertheless, p38
MAPK is capable of phosphorylating Smad3 (Mori et al., 2004)
or otherwise activating the apoptotic program by other means
(Zarubin and Han, 2005).
Although Smad3 was discovered 10 years ago as a major in-
tracellular mediator of TGF-b signaling (Zhang et al., 1996), the
role of Smad3 in tumorigenesis still remains elusive. Human ge-
netic studies have revealed both point mutations and deletions
of Smad2 and Smad4 in several types of cancers, but the inac-
tivating mutation of Smad3 has yet to be found (Riggins et al.,
1997). A recent study of T cell acute lymphoblastic leukemia in-
dicates that Smad3 protein, but not mRNA, is absent, suggest-
ing that changes in the Smad3 protein level rather than mRNA
may have an impact on carcinogenesis (Wolfraim et al., 2004).
Because target inactivation of Smad3 alleles causes premature
death in young adult mice due, at least in part, to compromised
immune functions (Yang et al., 1999), we elected to express
Smad3 and its mutants specifically in desired tissues to cir-
cumvent the obstacle presented by the loss-of-function ap-
proach to investigating the role of Smad3 in tumorigenesis.
Our data indicate that ectopic expression of Smad3 reduces
liver susceptibility to chemically induced carcinogenesis, pro-
viding direct in vivo evidence for a tumor suppression role of
Smad3.
HCC presents a major world public health problem because
of its prevalence in Asia, the Middle East, and Africa, and yet
the genetic lesions behind each step along the oncogenic trans-
formation of hepatocytes are not well understood due to the
complexity of HCC’s etiological origin (Thorgeirsson and Gri-
sham, 2002; Block et al., 2003). Our finding that ectopic expres-
sion of Smad3 can reduce liver susceptibility to carcinogenesis
in a chemically induced murine HCC model raises a hope of de-
signing a therapeutic strategy for treating HCC in human pa-
tients by invoking the TGF-b-induced apoptosis irrespective of
the underlying genetic causes. Escaping apoptosis is a critical
step in the progression to full malignancy of cancers, which
must overcome multiple fail-safe genetic controls. Upregulation
of Bcl-2 is one of the traits widely acquired by cancer cells to
evade apoptosis, as exemplified in follicular lymphoma, in which
a chromosome translocation brings the Bcl-2 structural gene
under the control of a constitutively active immunoglobulin
gene promoter (Graninger et al., 1987). The significance of
Bcl-2 as an anticancer target is reflected by the sheer number
of clinical trials designed for various strategies aiming at inacti-
vating Bcl-2 (Reed, 2002; Oltersdorf et al., 2005). However, di-
rect therapeutic use of TGF-b itself may be problematic because
it has a complex role in liver physiology. Prolonged exposure to
active TGF-b1 increases liver fibrosis and accelerates progres-
sion to cirrhosis, and also results in multiple extrahepatic lesions
due to elevated serum TGF-b levels (Sanderson et al., 1995; Ue-
berham et al., 2003). In contrast, our current study indicates that
Smad3, even when it is ectopically expressed at high levels, re-
mains dormant in normal adult hepatocytes and causes no ob-
vious health problems during the expected life span of the trans-
genic animals, making Smad3 a suitable gene therapeutic agent
for managing liver tumor growth.453
A R T I C L EFigure 8. Smad3 specifically represses Bcl-2 transcription via a GC-rich Smad binding element
A: Schematic representation of Bcl-2 promoters. Nucleotide coordinates are anchored to the Bcl-2 translational initiation site. The conserved GC-rich element
is underlined, and the Drosophila Mad binding consensus and inactivating mutations are shown.
B: Mapping of TGF-b-responsive element in the Bcl-2 promoter region in transfected Hep3B cells. TGF-b treatment lasted for 20 hr, and the promoter activity
was presented as the ratio of luciferase activity between TGF-b-treated and nontreated samples.
C: Reversal of the TGF-b-mediated transcription repression of Bcl-22802 reporter by Smad3-specific siRNA. Note that neither TGF-b nor Smad3 siRNA had any
effect on Bcl-2 2802m reporter, in which the GC-rich element was mutated.
D: Electrophoresis mobility shift assay for specific interaction between the purified GST-Smad3 DNA binding domain (Smad3NL) and DNA oligos containing the
GC-rich element. GST and GST-Smad2NL were used as controls. Competition by a 50-fold excess of unlabeled wild-type but not mutant (m or m2 as inA) DNA
probe, and supershift by anti-Smad3 antibody indicate specific binding of Smad3NL to the DNA. DNA-protein (shift) and antibody-induced supershift (ss) com-
plexes are marked.
E:ChIP assay for binding of Smad3 to the Bcl-2 promoter in vivo in the Fas-activated liver tissues. Animals were treated with Jo-2 antibody for 3 hr prior to being
sacrificed. PCR primers for amplifying Bcl-2 promoter are specified in the Experimental Procedures.
F: ChIP assay for binding of Smad3 to the Bcl-2 promoter in vivo in primary hepatocytes. Prior to TGF-b treatment for 1 hr, cells were cultured in the absence of
Dox for 24 hr to allow for the expression of Smad3 transgenes.
Error bars indicate mean 6 standard deviation.Experimental procedures
Transgenic mice
LAP-tTA mice were originally generated in H. Bujard’s laboratory (Kistner
et al., 1996) and bred to FVB/N predominant background. Plasmid pTRE-
Smad3, pTRE-F-Smad3SD, and pTRE-F-Smad3Dc were constructed by
subcloning wild-type Smad3, FLAG-tagged Smad3SD, or FLAG-tagged
Smad3DSSVS cDNA into pTRE2 (CLONTECH), respectively. Pronuclear in-
jection of linearized pTRE-Smad3, pTRE-F-Smad3SD, and pTRE-F-Smad3Dc
into FVB/N oocytes was performed at the NCI transgenic core facility. Founder
mice were identified by Southern blot of genomic DNA prepared from tails.
PCR genotyping primers for identifying tTA transgenes were described (Kist-
ner et al., 1996) and for Smad3 transgenes are 50-GTCAGATCGCCTGGA
GACGC-30 and 50-GTTTCTCCATCTTCACT-30, which amplify a 698 bp frag-
ment for TRE-Smad3 and a 717 bp fragment for TRE-F-Smad3SD and TRE-
F-Smad3Dc, respectively. All mice were maintained and handled according
to protocols approved by the NCI Animal Care and Use Committee.
RT-PCR
Total RNA for RT-PCR analysis was prepared from liver tissues using TRIzol
(Invitrogen). Total RNA (2.0 mg) was converted into cDNA using the454ThermoScript RT-PCR system (Invitrogen), and about one-tenth of the
cDNA was used in each PCR reaction. Primers are as follows: Smad3 trans-
genes, 50-AGCAGTGGAGCTGACACGGA-30 and 50-GGAGTGAATTCTTTG
CCAAA-30; Bcl-2, 50-TTCTCTCGTCGCTACCGTCG-30 and 50-CACTTGTGG
CCCAGGTATGC-30; Bcl-xl, 50-TTCCGACTGAAGAGTGAGCC-30 and 50-
TTCTCTCGTCGCTACCGTCG-30; Hprt, 50-TATGGACAGGACTGAAAGAC-
30 and 50-TAATCCAGCAGGTCAGCAAA-30.
Tumorigenesis and liver function assay
Expression of Smad3 transgenes in mice was activated by dietary withdrawal
of doxycycline (Dox) at 3 weeks of age. Diethylnitrosamine (Sigma) was made
into a 100 mg/ml solution with 0.9% NaCl, and a single dose was injected at
100 mg/kg body weight intraperitoneally into male mice at 5 weeks of age to
initiate tumor formation. Formation of tumors was promoted with 0.07% phe-
nobarbital (Sigma) given in diet when mice were 9 weeks old until mice were
sacrificed. Liver function was monitored by measuring serum alanine amino-
transferase (ALT) activities.
Histology and immunohistochemistry
Tissues were fixed in 10% buffered formalin, and 5 mm paraffin sections
were stained with hematoxylin and eosin (H&E). Tumors were counted inCANCER CELL JUNE 2006
A R T I C L EH&E-stained sections obtained from four different liver lobes for each mouse.
For immunohistochemistry, antibodies for Smad3 (Zymed), Bcl-2 (Santa
Cruz Biotech), Ki67 (Novocastra), phospho-JNK, and phospho-p38 (Cell Sig-
naling Technology) were used, and enzymatic staining (brown color) was per-
formed using DAB (Vector Lab) with hematoxylin counterstaining for nuclei
(blue color). Staining for active TGF-b1 was performed in frozen liver sections
as described (Ewan et al., 2002).
Hepatocyte isolation, cell culture, apoptosis, and proliferation assay
Hepatocytes were isolated by a two-step collagenase perfusion of the liver
(Kao et al., 1996) from mice fed with a diet containing Dox (Bioserve). Disso-
ciated cells were then plated in Collagen I-coated dishes in DMEM/F12 me-
dium supplemented with 10% FBS, 2 mg/ml Dox, and ITS+ (Collaborative Re-
search). To quantify apoptosis or proliferation, the cells were incubated for
24 hr in the DMEM/F12 medium containing 0.2% FBS in the presence or ab-
sence of Dox before harvesting for assay. Hep3B and SK-Hep-1 cells were
obtained from ATCC. Apoptosis assay was performed with the Cell Death
Detection ELISA assay kit (Roche), which quantitatively determines DNA
fragmentation using both anti-histone and peroxidase-conjugated anti-
DNA antibodies. Whenever indicated, TGF-b at 4 ng/ml was added to the
medium, and chemical inhibitors (Calbiochem) for p38 MAPK (SB 203580),
JNK (SP600125), ROCK (Y27632), Erk (U0126), and Akt were used at 10
mM each. Proliferation assays were carried out with 3H-thymidine labeling
as described (Danielpour et al., 1989).
ChIP and electrophoretic mobility shift assay
ChIP assays were carried out with a ChIP assay kit (Upstate). A pair of
primers (50-ACAGGACTTCTGCAAATGCT-30 and 50-AACCAGAGATCTCAA
GAGCA-30 were used to amplify a 98 bp fragment encompassing the GC-
rich repeat of the mouse Bcl-2 P2 promoter. Electrophoretic mobility shift as-
say was carried out as described (Zhang et al., 1998). Complementary DNA
oligos corresponding to the mouse sequence shown in Figure 7A were an-
nealed and labeled with g32P-ATP. One microliter of antibodies against
Smad3 or HA epitope tag was used in the supershift studies.
Transcription reporter assay and knockdown experiments
Luciferase reporter constructs containing 23934/28, 23934/21287, and
21278/28 segments of the Bcl-2 promoter were described by L. Boxer’s
laboratory (Heckman et al., 2000). The luciferase construct containing the
2747/28 segment was made by digestion of the 21278/28 construct with
SacI followed by ligation. Luciferase constructs containing the2802/28 seg-
ment and the mutants shown in Figure 4D were made by attaching annealed
oligos containing respective mutations at the SacI site of the 2747/28 con-
struct. Numbering of these constructs is relative to the translation start site.
Transfection of Hep3B or SK-Hep-1 cells was performed with Fugene 6
(Roche) in 12-well plates. Oligofectamine (Invitrogen) was used for siRNA
transfection experiments (Elbashir et al., 2001). The target sequences of
siRNA (Cellogenetics) against both human and mouse Smad2 and Smad3
are 50-AACAGGCCTTTACAGCTTCTC-30 and 50-AAGGCCATCACCACGCA
GAAC-30, respectively. The nonsilencing siRNA, which does not target any
known mammalian gene, was used as the control.
In vivo Jo-2 injection and apoptosis assay
Fas-induced cell death was initiated by intraperitoneal injection of Jo-2 mAb
(Pharmingen) at 0.15 mg/kg body weight into mice 3–4 months of age.
TUNEL assay on paraffin sections was performed with the In Situ Cell Death
Detection Kit (Roche) for demonstrating apoptotic cell death in the liver. Liver
lysates were used in Western analyses of caspase cleavage with antibodies
specific for caspase-8 (Santa Cruz Biotech), caspase-9, and caspase-3 (Cell
Signaling Technology).
Retroviral and adenoviral infections
LPCX-puro derived retroviral vectors were used for expressing FLAG-tagged
Smad3 and Smad3Dc as described (Choy et al., 2000). Two days after infec-
tion of SK-Hep-1 cells, puromycin (2.5 mg/ml) was added for 3 days, and the
selected cells were then plated in 12-well plates for Western blot. Recombi-
nant adenovirus for Bcl-2 was kindly provided by Drs. K. Suh and S. Yuspa
(Suh et al., 2004), and infections of Hep3B and SK-Hep-1 cells were con-
ducted as described (Fujii et al., 1999).CANCER CELL JUNE 2006Statistical analysis
Student’s t test was used for statistical analysis. All bar graphs are displayed
as mean 6 standard deviation.
Supplemental data
The Supplemental Data include two supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/9/6/445/
DC1/.
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